These results were similar to those from Kohli  et al. [57] who demonstrated that high sST2 levels (i.e., >35 μg/L) in NSTE-ACS patients predicted a >3-fold higher risk of cardiovascular death and heart failure at 30 days and 1 year, even after adjustment for major clinical risk factors and biomarkers (cTnI and BNP) [57]. This evidence concerns the gene NPPB and heart failure.